Live Rate
| Open | |
|---|---|
| High | |
| Low | |
| Prev. Close | |
| Lower circuit | |
| Upper circuit | |
| 52w High | |
| 52w Low | |
| P/E Ratio |
Listing Price
| Exchange | Listing Price | Gain/Loss | % |
|---|---|---|---|
| NSE | ₹132.50 | +₹36.50 | +38.02% |
Subscription
Last updated on 20-Jun-2025 18:26:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 1159200 | 159818400 | 137.87 |
| NIB | 870000 | 418572000 | 481.12 |
| RETAIL | 2029200 | 238842000 | 117.7 |
| Total | 4058400 | 817232400 | 201.37 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 99 |
| NIB | 21204 |
| RETAIL | 199035 |
| Total | 220338 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 11.13 | 1534.26 | 137.87 |
| FII | - | 414.05 | - |
| FI | - | 77.24 | - |
| IC | - | 20.19 | - |
| MF | - | 0 | - |
| OTH | - | 1022.77 | - |
| NIB | 8.35 | 4018.29 | 481.12 |
| RETAIL | 19.48 | 2292.88 | 117.7 |
| Total | 38.96 | 7845.43 | 201.37 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹17.8 | @8% ₹20.3 | @9% ₹22.8 | @10% ₹25.4 | @11% ₹27.9 | @12% ₹30.5 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹62 | @8% ₹70.9 | @9% ₹79.7 | @10% ₹88.6 | @11% ₹97.4 | @12% ₹106.3 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail (10000 to 2 lakh) | 1 | 1200 | 115200 | 1691 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| RETAIL | 33.26% | 2029200 |
| HNI | 14.26% | 870000 |
| ANCHOR | 28.46% | 1736400 |
| QIB | 19.00% | 1159200 |
| MARKET MAKER | 5.02% | 306000 |
| Total | 100.00% | 6100800 |
IPO Details
| Issue Size | 61,00,800 shares (aggregating up to ₹58.57 Cr) |
| Fresh Issue | 50,00,400 shares (aggregating up to ₹48.00 Cr) |
| Offer for Sale | 11,00,400 shares of ₹10 (aggregating up to ₹10.56 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,81,50,000 shares |
| Share Holding Post Issue | 2,31,50,400 shares |
| Market Maker Portion | 3,06,000 shares |
| Market Maker | R.K Stock Holding |
Key Performance Indicator (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 36.98% | 48.85% | 61.76% |
| ROCE | 49.17% | 65.58% | 78.60% |
| RONW | 36.98% | 48.85% | 61.76% |
| EPS (basic) | 7.36 | 6.13 | 3.96 |
| P/E Pre IPO | 13.04 | ||
| P/E Post IPO | 16.63 |
Company Financials In Crores
| Period Ended | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| Assets | 70.3 | 41.1 | 28.3 |
| Revenue | 105.0 | 100.1 | 76.1 |
| Profit After Tax | 13.4 | 11.2 | 7.2 |
| Net Worth | 36.2 | 22.9 | 11.7 |
| Reserves and Surplus | 18.0 | 22.9 | 11.6 |
| Total Borrowing | 0.2 | 0.3 | 0.8 |
About Company
Company Background
Incorporation: September 2020
Core Business: Contract Development and Manufacturing (CDMO) for nutraceuticals, cosmetics, and pharmaceuticals.
Facilities: Three manufacturing units in Thane, Maharashtra (9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft.).
Product Portfolio
Influx Healthtech manufactures a wide range of products, including:
Pharmaceuticals: Tablets, capsules, powders, liquid orals, softgels, oral films.
Nutraceuticals: Sports supplements, gummies, veterinary feed.
Cosmetics: Skincare, haircare, beard care, face masks.
Ayurveda/Herbal: Traditional formulations.
Homecare: Hygiene and wellness solutions.
Key Clients (As of March 2024)
Bling Brands, Evoq Ventures, HSHS Nutraceuticals, Bruder Life Science, and Bigflex Lifescience.
Strength
Diversified Product Portfolio: Broad offerings across pharmaceuticals, nutraceuticals, and cosmetics.
Established Clientele: Strong ties with reputed health and wellness brands ensure business stability.
Robust Quality Assurance: Adherence to GMP, FSSAI, and other standards through strict QA/QC systems.
Weakness
Intense Competition: Faces strong competition from larger CDMOs like Jubilant and Divi’s Labs.
Raw Material Volatility: Fluctuating input prices may impact margins and profitability.
Client Dependency: Over-reliance on select customers could affect stability if contracts are lost.
Latest Announcements
| Date | Subject | Attachment Text |
|---|
Financial Results
Lead Manager(s)
Address
109, Ghanshyam Enclave Premises Co-op
Soc Plot No. 856, Laljipada
Kandivali West,
Mumbai, Maharashtra
Phone: +91 7045997809
Email: cs@influxhealthtech.com
Website: https://influxhealthtech.com/